We are comparing two dosing schedules of adagrasib for patients with non-small cell lung cancer and a KRAS G12C mutation who have had previous treatments. The goal is to find out which regimen works better and is safer.
Health conditions and diseases that the clinical trial is designed to study and treat.
Non-small cell lung cancer (NSCLC) is a type of lung cancer that begins in the cells of the lungs and is characterized by the uncontrolled growth of abnormal cells. It can spread to other parts of the body, leading to more serious health issues.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
